anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is to be a 12-week, phase II, multicentre, randomised, double blind, efficacy and safety study of CPL409116 in participants with active rheumatoid arthritis who are taking methotrexate but have an inadequate response to this drug. Eligible subjects are to be randomised into one of the 4 treatment arms (60 mg BID, 120 mg BID, 240 mg BID of CPL409116 or palcebo) and approximately 100 male and female subjects are to be enrolled in the study (25 patients per arm). The study is to include the screening period, the treatment period and the follow-up period. In all treatment arms the investigated product/ placebo is to be administered orally for 12 weeks in a blinded fashion. In order to maintain the blind and minimize bias, all subjects will receive the same number and types of tablets each day of treatment. In the screening period, patients are to undergo screening assessments from Day -28 to Day 0. Rolling admission is to be employed in this study. Patients that fulfil all the inclusion criteria and none of the exclusion criteria will be considered eligible for this study. During the treatment period, patients are to be dosed with 60, 120, 240 mg CPL409116 administered twice a day or placebo administered twice a day for 85 consecutive days (Day 1 to Day 85). The MTX dosage which should be orally or parenterally administered by participants during the study and before the start of the study should be in the range of 15-25 mg/ week, which is typical of current clinical practice. MTX must be applied for at least 12 weeks prior to Screening, and with no change in dosage and route of administration for at least 8 weeks prior to Day 1/ baseline. Within the follow-up period patients are to undergo safety assessment for 4 weeks after the last dose of IMP.
Risk Summary

Lidocaine is excreted into human milk. When lidocaine was used as an epidural anesthetic for cesarean section in 27 women, a milk:plasma ratio of 1.07 was observed using AUC values. Lactating women undergoing a dental procedure had a 0.4 milk:plasma ratio. In another dental procedure study, a single patient was administered 20 mg of lidocaine and the milk:plasma ratio was reported as 1.1 at five to six hours after injection. These data, and the low concentrations of lidocaine in the plasma after topical administration of ZTLIDO in recommended doses, suggest that a small amount of lidocaine would be ingested orally by a suckling infant. However, caution should be exercised when ZTLIDO is administered to a nursing mother, especially when administered with other local anesthetics.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to oncology, and can be used in treatment of patients with generalised (disseminated) forms of renal cell carcinoma. Method is realised in the following way. Reaferon is introduced to patients intramuscularly, starting with 1 mln U, under control of body temperature dynamics and content of lymphocytes in leukocyte formula of blood. Reaferon dose is increased on 1 mln U with each next, in 1-2 days introduction, until body temperature rises to 37.5-38.0 degrees Celsius and will remain such during 2-3 hours after reaferon introduction, content of lymphocytes in leukocyte formula of blood a day after introduction being within 21-33%. ^ EFFECT: application of invention allows to reduce dimensions of metastases with monotherapy with reaferon due to adjustment of optimal reaferon dose depending on adaptive response of organism, reduce number of side effects and complications. ^ 1 ex
Calciphylaxis, also known as Calcific uremic arteriolopathy (CUA), is a serious disorder that presents with skin necrosis due to calcification of dermal and subcutaneous adipose tissue capillaries and arterioles. The condition occurs primarily in patients with end-stage renal disease (ESRD) on dialysis, and it carries high morbidity and mortality, primarily due to sepsis, with an estimated six-month survival of approximately 50%. Although there are no high-quality studies to guide the optimal treatment approach for patients with calciphylaxis, many retrospective studies and case series support treatment with sodium thiosulfate (STS). Despite the frequent use of STS as an off-label treatment, data regarding its safety and efficacy are limited. STS has generally been considered a safe drug with mild side effects. However, severe metabolic acidosis associated with STS is a rare and life-threatening complication of STS treatment and is often unpredictable. Herein, we report a 64-year-old female with ESRD on peritoneal dialysis (PD) who presented with a profound high anion gap metabolic acidosis and severe hyperkalemia while on STS treatment for CUA. No other etiology for her severe metabolic acidosis other than STS was identified. ESRD patients receiving STS should be monitored closely for this side effect. Dose reduction, increasing the duration of infusion, or even discontinuing STS treatment should be considered if severe metabolic acidosis develops.
OBJECTIVE: Obesity, chronic inflammation, and oxidative stress can influence mitochondrial DNA (mtDNA) content. Our objective was to evaluate the oxidation level and content of mtDNA and its relationship with metabolic parameters in metabolically healthy obese (MHO) compared to metabolically unhealthy obese (MUO) and normal weight (NW) controls.
MATERIALS AND METHODS: We studied 94 NW, 95 MHO, and 97 MUO individuals between 18 and 80 years old. Relative mtDNA content and mtDNA oxidation level (8-oxoguanine, 8-OxoG) were determined in peripheral blood leukocytes by the SYBR Green method of real-time PCR. One-way ANOVA and Tukey test were used to compare biochemical, clinical, and anthropometric characteristics, as well as mtDNA content and 8-OxoG.
RESULTS: A progressive decrease in mtDNA content was observed between NW, MHO, and MUO with significant differences in MUO vs. NW (p: 0.04). An increase in 8-OxoG was observed in MUO patients compared to the other groups (MUO vs. MHO p: 0.01; MUO vs. NW p: 0.04). mtDNA content was directly correlated with HDL-c (p < 0.01) and inversely with waist circumference (p: 0.01) and LDL-c (p: 0.05). mtDNA content decreased, and the oxidation level increased concomitantly with the presence of obesity, the number of MS components, higher coronary risk, and insulin resistance parameters.
CONCLUSION: MHO presented a similar mtDNA oxidation level to NW and mtDNA content to the MUO, placing the MHO individuals as having an intermediate phenotype. Changes in mtDNA content and oxidation were correlated to the lipid profile related to obesity and/or MS presence, probably associated with oxidative stress and chronic low-grade inflammation.
Tobacco use is widely recognized as the most preventable cause of cancer in the United States. Furthermore, tobacco use is responsible for 30% of all cancer-related deaths in the United States. Although practice guidelines recommend that clinicians address tobacco use during all outpatient clinic visits, the realities of the clinic setting make this difficult for overworked and overstretched clinical personnel. A computer-based intervention may enhance patient care by decreasing this burden and priming patients and families for a discussion about smoking cessation with their physician. Previous research has demonstrated the feasibility of developing and implementing an interactive computer-based program to facilitate smoking cessation in the outpatient clinic setting. The program can be self-administered, presents minimal burden to existing staff, and meets the Public Health Service practice guidelines. Furthermore, this intervention was found to be effective at increasing readiness to change in parental smoking behavior. The overall objective of this proposal is to further develop the program and test this interactive computer-based program to facilitate motivation and readiness to cease tobacco use and engage in parental smoking cessation services. The current computer program focuses on the assessment of the participant's smoking behavior and the delivery of personalized feedback regarding their smoking behavior. Modifications to the new program will include the removal of the carbon monoxide testing, inclusion of all baseline and follow-up assessment into the computer-based program (creating a single, stand-alone package that further reduces staff burden), and the inclusion of a link directly to the Oklahoma Tobacco Settlement Endowment Trust "click to call" option (allowing patients to immediately self-refer for cessation support). Parents of children presenting to a general pediatric outpatient clinic, who self-report as current smokers, will be recruited for a randomized controlled trial to assess the effectiveness of the revised computer-based program. It is proposed that exposure to this brief intervention will result in increasing smokers' readiness to cease tobacco use and engage in smoking cessation services. The successful completion of the proposed project will result in the development of a smoking cessation intervention that can be easily and consistently delivered, in a host of different settings, with little burden to existing staff. The successful development of such an intervention directly relates to the OTRC Mission and Goals and specifically fits with two of the OTRC's primary research areas: prevention and cessation of tobacco use and tobacco-related health disparities in Oklahoma's diverse populations and reduction of secondhand smoke exposure.
Patients receive veliparib PO BID on days 1-5. Patients also receive paclitaxel IV and carboplatin IV on day 3 (course 1 only) or day 4 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity. Beginning 21 days after the last course, patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Results from a population-based 2-year clinical trial, the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER), demonstrated that a multidomain intervention of physical activity, nutritional guidance, cognitive training, social activities and management of vascular risk factors slowed cognitive decline in healthy older adults at increased risk of cognitive decline. Currently, no pharmacological treatment options that can rival these effects. Thus, there is an urgent need to test the generalizability, adaptability, and sustainability of these findings in Singaporean populations. A 6-month pilot study was initiated in Singapore, which demonstrated the cultural feasibility and practicality of the FINGER interventions and a set of locally adapted interventions in an Asian population. Hence, the next step was to conduct a larger scale SINGER trial to determine the efficacy of these interventions in Singapore. If the interventions are found to be effective and safe with high applicability and scalability, the study will provide important clinical and public health implications to a rapidly increasing ageing population.
PROBLEM TO BE SOLVED: To obtain the subject preparation less prone to be discolored with light and useful as a cosmetic little in a foreign smell by stably compounding a beautifully whitening agent. SOLUTION: This preparation for external uses for skins contains one or more kinds of compounds selected from the group consisting of L-ascorbic acid and its derivative (e.g. a L-ascorbic acid alkyl ester), hydroquinone glycoside and its derivative (e.g. hydroquinone α-D-glucose), kojic acid and its derivative (e.g. a kojic acid alkyl ester), an UV light absorbent and dibutylhydroxytoluene. The further addition of one or more kinds of compounds selected from a metal ion-blocking agent, a divalent metal salt, a trivalent metal salt, sulfurous acid and its salt, hydrogen sulfite and its salt, thiosulfuric acid and its salt, pyrosulfurous acid and its salt to the preparation for the external uses furthermore improves the stability of the contained derivative.
BACKGROUND: Lumbar revision surgery can be performed by simple lumbar nerve decompression or lumbar interbody fusion, including percutaneous endoscopic lumbar discectomy, transforaminal lumbar interbody fusion (TLIF), etc. However, lumbar revision surgery is very difficult in surgical operation. We sought to explore the technique safety and efficacy of microscope-assisted minimally invasive transforaminal lumbar interbody fusion (MI-TLIF) in lumbar revision surgery.
METHODS: Cases of postoperative recurrence following lumbar spine surgery (n = 63) treated from December 2016 to July 2021 were retrospectively analyzed, including 24 cases of microscope-assisted MI-TLIF (microscopic group) and 39 cases of naked-eye MI-TLIF (naked-eye group). The operation time, intraoperative blood loss, incision length, postoperative drainage, length of hospital stay, initial operation, and visual analog score (VAS) of low back and leg pain before and at 7 days and 3 months after the operation and the last follow-up were compared between the two groups. The Oswestry Dysfunction Index (ODI) and the Japanese Orthopaedic Association (JOA) scores before and after the operation and the Bridwell interbody fusion grades at 1 year were compared. The independent t tests, Mann-Whitney U tests, and Chi-square tests were used for analysis.
RESULTS: All 63 patients were successfully treated by operation and were followed up for an average of 31.5 ± 8.6 months (range 12-48 months). The two groups had no significant difference in sex, age, incision length, initial operation, or operative segment (P > 0.05). There was no significance in operation time, VAS score, ODI score, and JOA score of low back pain or Bridwell interbody fusion grade between the two groups (P > 0.05). Significant differences in intraoperative blood loss, postoperative drainage, and the lengths of hospital stay were observed between the two groups (P < 0.05). Cerebrospinal fluid leakage (n = 2), edema of nerve roots (n = 2), and incision infection (n = 1) were observed in the naked-eye group. There were no complications in the microscopic group, such as cerebrospinal fluid leakage, edema of nerve roots, and incision infection.
CONCLUSION: Although microscope-assisted MI-TLIF and naked-eye MI-TLIF are both effective during lumbar revision surgery, microscope-assisted MI-TLIF brings less trauma, less bleeding, shorter postoperative hospital stay, and faster recovery. Unlike traditional surgery, microscope-assisted MI-TLIF provides a clear visual field, adequate hemostasis, and nerve decompression.
The invention discloses a preparation technology of herba epimedii traditional Chinese medicine capsules. According to special medicinal functions and effects of a traditional Chinese medicine herba epimedii, a medicinal health product of herba epimedii traditional Chinese medicine capsules is prepared by taking the traditional Chinese medicine herba epimedii as a raw material which is scientifically matched with quantitative proportional auxiliary traditional Chinese medicinal materials through a series of preparation technical steps. The product contains various Chinese herb medicinal materials, more active medicinal substances and rich mineral substances required by a human body. The capsules eaten have the functions of activating spirit, increasing and filling marrow, replenishing and engendering essence, securing and activating essence, nourishing yin and tonifying Yang, tonifying brain and improving eyesight, resisting diseases and prolonging life, building body, maintaining beauty and keeping young and the like. The product is scientific in formula and reasonable in match. As the product is prepared into an ultrafine powder medicine, the nutritional substances are fully and effectively refined, so that the effective nutritional substances and elements do not run off and various effective active substances are easily absorbed by the human body and quick to use. The capsules taken are remarkable in medicinal curative effect, promote body building and are very obvious in medical and medicinal health effects.
Compressed nitrogen is used to create a 'cryogenic needle', using a cryopunctor device. An orifice is placed in appropriate acupoint and nitrogen flow is used to cool and activate the point. This will occur on each ear with the following points being targeted: Omega 2, Omega, spine location point, and 3 points of the pain pathway including the sensory master point (SMP), the master point of the reticule (MPR), and the thalamus (T) as well as the corpus callosum (CC) point, the amygdala, rhinencephalon, hippocampus, FSHLH, ACTH, anterior and posterior white commissure points, and the corresponding sympathetic sensory and motor nerve points.
Steroid sapogenins and industrially useful by-products are recovered from vegetable material containing saponins by a simultaneous extraction and hydrolysis, using a mixture of H2SO4 and a lower alkanol. Vapour from the alcohol extracts the saponin and the extract is hydrolysed by the acid, the acid not being permitted to come into contact with the vegetable material. The spogenins are recovered from the extract together with an insoluble residue. Sapogenins are starting materials for steroids, e.g. cortisones, sex hormones and contraceptives. The by-products from this process are proteins, suitable for animal feeds, and unsaturated oils, suitable for the manufacture of soaps, perfumes, paints, varnishes and foodstuffs. Better recovery of sapogenins is obtd. with less formation of spirosta-3,5-dienes. The extraction is usually carried out in a Soxhlet extractor, using a mixture of 0.5-3.0 N. H2SO4 and 30-95% lower a alcohol. In an example seeds of Papilionaceae were crushed and extracted in a Soxhlet with 150 ml 1.4N H2SO4 in 95% ethanol. The recovery of sapogenins was 0.8% on weight of seed, compared to 0.4% for conventional extn.
The observational group may include those 18 years and older, with retrospective MRI data, or those whom prospective MRI images are collected as a participant. This study is decentralized, non-therapeutic and non-interventional.
In this application, the investigators propose to further validate and expand upon one of the apparent striking successes of translational research. Specifically, basic research on the neural circuitry underlying fear extinction led to the examination of d-cycloserine (DCS), a partial agonist of the NMDA receptor in the amygdala, as an agent capable of enhancing extinction learning (Davis et al., 2006; Davis et al., in press). Following successful validation of this strategy in the animal laboratory (see Ledgerwood et al., 2005; Richardson et al., 2004), Ressler et al. (2004) showed that single doses of d-cycloserine (DCS) could enhance extinction in a human exposure paradigm for height phobic adults. This exciting initial finding was replicated by this research team for the treatment of social anxiety disorder (Hofmann et al., 2006), as well as an initial pilot study of the treatment of panic disorder (Tolin et al., 2006). As discussed by Anderson and Insel (2006), these findings have the potential to foster significant advances in the treatment of anxiety disorders. The present study represents the further application of DCS for augmenting the effects of exposure-based cognitive-behavior therapy (CBT), now applied to the treatment of panic disorder with or without agoraphobia.

In the current application, the investigators propose a five-year study to show the acute and longer-term effects of DCS augmentation of exposure-based CBT relative to placebo augmentation. This study is noteworthy for the use of a brief treatment strategy that has been shown to be successful in previous trials (e.g., Clark et al., 1999; Roy-Byrne et al., 2005) and has served as the basis for the DCS augmentation effect seen in a pilot study for this application. By demonstrating that DCS can enhance the results of even a brief treatment strategy, the investigators are seeking to validate an approach that fits well with the practice limitations and applications of CBT in effectiveness studies (e.g., Katon et al., 2006; Roy-Byrne et al. 2005). Furthermore, by studying the genetic predictors of the overall response to CBT, and DCS augmentation in particular, the investigators hope to further elucidate the nature of DCS augmentation and the selection of particularly responsive subgroups of patients in need. This agenda is in accords with "the ultimate goal of personalized therapy: identifying individual patterns of pathophysiology that indicate which pharmacological or behavioral treatment will be most useful for any individual patient" (Anderson \& Insel, 2006, p. 320).

The study design is a double blind, randomized, controlled, trial conducted at three treatment sites. Patient with panic disorder will randomly receive DCS or placebo 1 hour prior to sessions 3-5 of a 5-session CBT protocol that includes 2 additional booster sessions over the course of follow-up. Patients will be enrolled over 5 years with the identical treatment protocol followed at each of the sites. Sites will nonetheless differ with respect to study management and analysis procedures.
PURPOSE OF REVIEW: To review popular dietary trends and provide recommendations regarding validated dietary approaches for weight loss in the pediatric population.
RECENT FINDINGS: Like adults, children and adolescents trying to lose weight will succumb to diets promoted by the media. Many of these so-called "fad" diets tout unsupported claims for health but prove very difficult for long-term adherence. Since childhood is a pivotal time for establishing lifestyle habits, we need to provide practical dietary advice supported by scientific research. Studies suggest that emphasizing macronutrient balance while limiting both ultraprocessed foods and sugar-sweetened beverages can help our pediatric patients achieve and maintain a healthy weight. We review literature discouraging the use of restrictive dieting in the pediatric population and instead encourage a whole-foods-based, balanced dietary approach, along with regular physical activity. The goal is to support reasonable and sustainable lifestyle habits that ultimately allow children to establish lifelong health-promoting behaviors.
NEW MATERIAL:A compound of formula I (m is 0, 1; n is 1-10; l is 12-20). EXAMPLE:1-Palmitoyl-2-[9-(p-vinylbenzoylnonanoyl]-glycero-3-phosphocho line. USE:A compound which can form microcapsules sued as a carrier for a variety of compounds, because of its high photopolymerization rate. PREPARATION:The condensation reaction between an acid chloride of formula IIand glycerol derivative of formula III gives a compound of formula I . A medicinal substance or enzyme is encapsulated into this substance and used as a drug or in clinical assays. Further, encapsulation of photosensitive materials or dyes gives brighter and clearer photographs and printed images.
As for intravitreal ranibizumab 0.5 mg (IVR), we use OCT-guided treat-and-extend protocol for DME treatment after modifying the settings of TREX-DME study.4 The regimen include 3 monthly loading doses then extending the treatment injection interval one month more if CFT less than 350 μm without obvious submacular fluid and intramacular cysts. The injection interval shorten one month if CFT more than 350 μm or presence of obvious fluid and/or cysts. The patients are intentionally injected at most every 3 months even DME not existing.